Medigene AG (0QGJ.L)
| Previous close | 1.6150 |
| Open | 1.5600 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.5250 - 1.5600 |
| 52-week range | 1.3850 - 2.2500 |
| Volume | |
| Avg. volume | 128 |
| Market cap | 374,495 |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4060 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireMedigene presents streamlined 6-day, high stemness TCR-T therapy production process
Planegg/Martinsried, April 25, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents a comprehensive overview of its lead candidate MDG1015, a first-in-class 3rd generation T cell receptor engineered T cell (TCR-T) therapy, at CHI's 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London. MDG1015, which is advancing toward
- GlobeNewswire
Medigene to Present at Upcoming Scientific Conferences
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been invited to present at the CHI's 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London, UK, as well as at the 7th International Neoantigen Summit to be held in Amsterdam, Netherlands from April 29 - May 1, 2024. The presentations will be available on Medigene´s website after the c
- GlobeNewswire
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents superior recombinant T cell receptor (rTCR) engineered T cell functionality as well as a favorable safety profile when rTCR-T cells are armored and enhanced with the PD1-41BB costimulatory switch protein (CSP) at the American Association for Cancer Research (
